Pharma Q2 Outlook: Mixed Growth Amid Pricing Pressure and US Competition
India's pharmaceutical sector is set for mixed results in the September quarter. Sun Pharmaceutical Industries and Aurobindo Pharma are expected to show strong growth, while Dr Reddy's Laboratories and Lupin may struggle due to heightened competition and a high base. Pricing pressures and rising raw material costs are likely to affect overall industry performance.
ET Markets·



